Medivation's Dimebon Meets All Five Efficacy Endpoints in Phase 2 Alzheimer's Disease Study

Medivation's Dimebon Meets All Five Efficacy Endpoints in Phase 2 Alzheimer's Disease Study: "Medivation, Inc. (AMEX:MDV) today announced that its proprietary drug Dimebon(TM) met all five efficacy endpoints in a six-month randomized, double-blinded, placebo-controlled Phase 2 clinical study of 183 patients with mild to moderate Alzheimer's disease conducted at 11 sites in Russia"